Camlin Fine Sciences Ltd (Chemicals - Others) — fundamental analysis, earnings data, and key metrics. PE: 855.0. ROE: -15.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Deep value thesis based on recent earnings • Updated Mar 21, 2026
Temporary operational disruptions mask an emerging margin recovery in Vanillin business with US tariff relief expected to catalyze earnings inflection in Q4 FY26.
Verdict
EARLY_INNINGS
Re-rating catalysts over the next 2-4 quarters • Updated Mar 21, 2026
Expected reduction from 25% to 18% will boost Vanillin export margins by ~700 bps, potentially adding Rs. 50-70 cr to annual EBITDA
Impact: +₹50 Cr revenue
“Management guidance on tariff relief and Vanillin business recovery”
Full-quarter contribution from natural ingredients portfolio expected to lift specialty ingredients revenue by 15% with 20%+ EBITDA margins
“Vinpai acquisition strengthens natural ingredients portfolio”
Management targeting D/E below 0.5x by FY27 end from current 0.65x, potentially triggering credit rating upgrade
“Long-term debt reduced from Rs. 332.72 cr to Rs. 268.30 cr”
Risks that could prevent re-rating or deepen the value trap
Continued pricing pressure in commoditized Straights segment
Impact: -1070 bps margin impact
Management view: Management focusing on Value Added Blends to offset Straights decline
Monitor: Straights segment revenue trend
Continued operational disruptions affecting working capital cycle
Management view: Management expects improvement as Brazil fire incident effects subside
Monitor: CFO to PAT ratio
Further increase in promoter pledge or related party transactions
Management view: Not explicitly addressed in recent communications
Monitor: Promoter pledge percentage
Forward-looking targets from management for FY27
Revenue Growth Target
8%
Implied PAT Growth
250%
OPM Guidance
8.5%
Capex Plan
₹150 Cr
Key Milestones
• US tariff relief realization
• Vinpai integration completion
• D/E below 0.5x achievement
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Mar 21, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Camlin Fine Sciences Ltd's latest quarterly results (Dec 2025) show
Camlin Fine Sciences Ltd's current PE ratio is 855.0x.
Camlin Fine Sciences Ltd's price-to-book ratio is 2.3x.
Camlin Fine Sciences Ltd's fundamental strength based on key financial ratios
Camlin Fine Sciences Ltd has a debt-to-equity ratio of N/A.
Camlin Fine Sciences Ltd's return ratios over recent years
Camlin Fine Sciences Ltd's operating cash flow is positive (FY2025).
Camlin Fine Sciences Ltd currently does not pay a significant dividend (yield 0.00%).
Camlin Fine Sciences Ltd's shareholding pattern (Dec 2025)
Camlin Fine Sciences Ltd's promoter holding has decreased recently.
Camlin Fine Sciences Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Camlin Fine Sciences Ltd has 3 key growth catalysts identified from recent earnings analysis
Camlin Fine Sciences Ltd has 3 key risks worth monitoring
Camlin Fine Sciences Ltd's management has provided the following forward guidance for FY27
Based on quantitative research signals, here is why Camlin Fine Sciences Ltd may be worth studying
Camlin Fine Sciences Ltd investment thesis summary:
Camlin Fine Sciences Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
